Samuel S. Engel
Merck & Co., Inc., Rahway, NJ, USA (United States)
ORCID: 0000-0002-4439-6356Also affiliated with Deutsche Rheuma-Liga
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 3 papers. Top paper: “Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK‐3655 in Individuals With Pre‐Cirrhotic MASH”.
Ira Gantz, Michael Crutchlow, Heather Flynn, Lianzhe Xu, Anthony J. Rodgers +6 more
Yuliya Lokhnygina, Tsvetalina Tankova, Jennifer B. Green, Pablo Aschner, Keyur P. Patel +10 more
Serene Lek, Charlene Z. L. Ong, Chun Kit Wong, Yongqi Zhou, Aileen Wee +19 more